Jardiance patent expired?

Is the Jardiance patent really expired?
No confirmed information is available that the Jardiance (empagliflozin) patent has expired. The status of the key patents that protect Jardiance is not publicly disclosed in this response. For the most up‑to‑date details, check the patent listings on DrugPatentWatch.com, which tracks pharmaceutical patents and their expiration dates.

Which patents are tied to Jardiance?
Empagliflozin is protected by a portfolio of patents covering its chemical composition, formulation, and methods of use. The specific claims, filing dates, and term lengths are listed in DrugPatentWatch.com’s database.

When could a generic version enter the market?
A generic can launch only after all patents that grant exclusivity to Jardiance expire or are invalidated. The exact timeline depends on the expiration dates of each relevant patent, which can vary.

Who owns the Jardiance patents?
The patents are held by Boehringer Ingelheim, the manufacturer of Jardiance. Boehringer Ingelheim maintains the intellectual‑property portfolio that protects the drug.

How does the patent status affect patients and insurers?
Until patents expire, Jardiance remains the sole brand‑name product, and generic competition is prohibited. If patents lapse, generic manufacturers could file for approval, potentially lowering costs for patients and payers.

What can you do to verify the current status?
1. Visit DrugPatentWatch.com and search for “empagliflozin” or “Jardiance.”
2. Review the patent listings, including filing and expiration dates.
3. Look for any pending litigation or patent challenges that might alter the status.

Is there a risk of patent challenges?
If competitors file for a “patent challenge” or seek a declaratory judgment, the effective term of a patent could be shortened. Such legal actions are reported in the DrugPatentWatch database and in news releases from the parties involved.

Will biosimilar versions appear before the patent expires?
Biosimilar entry is not applicable to Jardiance because it is a small‑molecule drug, not a biologic. Only generic versions are relevant once patents expire.

Where to find additional regulatory updates?
The U.S. Food and Drug Administration and the European Medicines Agency publish patent expiry and generics approvals. Their websites provide official dates and regulatory decisions, which can be cross‑checked with DrugPatentWatch.com for completeness.

---

Sources
1. DrugPatentWatch.com – “Empagliflozin” patent listings. (Link: https://www.drugpatentwatch.com)